- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02883660
Genecept Assay and Adverse Effects of Antidepressants
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 18 years or older
- Able to give informed consent prior to the initiation of any protocol required procedures.
- Subject must be able to understand the nature of the study, agree to comply with the study procedures, and communicate about medical history to the study personnel.
- Subject was treated with one of the following "target antidepressants:" Escitalopram, citalopram, paroxetine, fluvoxamine, venlafaxine, duloxetine, bupropion, vortioxetine, vilazodone, and levomilnacipran. Rationale: These antidepressants are primarily metabolized by CYP isoenzymes that will be assessed. Antidepressants like sertraline, fluoxetine, and mirtazapine are metabolized by multiple CYP isoenzymes and therefore are less likely to be significantly affected by metabolizer status on a particular CYP isoenzyme. For patients who have been treated with multiple antidepressants, the antidepressant that was associated with the greatest overall burden of AEs will be selected as the target antidepressant.
5a. Study group: "Increased AEs" currently or in the past on one of the target antidepressants as operationally defined as either A or B: A) One or more AEs that were moderate/severe OR three or more AEs that were mild occurring on less than the usual minimum recommended dose of the antidepressant, or B) Three or more AEs that were moderate/severe OR five or more AEs that were mild on a dose of the antidepressant within the usual recommended dose 5b. Control group: Both A and B A. Less than 30% reduction in the severity of depression after treatment for at least 6 weeks B. Minimal or no AEs on that antidepressant
Exclusion Criteria:
- Subjects on antidepressants other than those specified in the inclusion criteria.
- Subjects for whom it is unclear which medication caused the adverse events
- Subjects for whom participation in the study would be detrimental to their mental of physical health based on investigator's opinion
- Subjects who have had a medical condition that, in the investigator's judgment, may be causing the reported adverse events
- Prisoners or patients who are involuntarily incarcerated
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cases
patients who had empirically defined "increased AEs" on one of the specified antidepressants (SSRIs/ SNRIs).
This group will get the Genecept Assay, which is a battery of pharmacogenetic tests relevant to psychiatry.
|
battery of pharmacogenetic tests relevant to psychiatry
|
Controls
patients who did not have empirically defined "increased AEs" with an index antidepressant (one of the specified SSRIs/ SNRIs) AND were "nonresponders" to that antidepressant.
This group will get the Genecept Assay, which is a battery of pharmacogenetic tests relevant to psychiatry.
|
battery of pharmacogenetic tests relevant to psychiatry
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Poor metabolizers have more side effects
Time Frame: through study completion, approximately 2 years
|
Our primary aim is to test the hypothesis that a statistically significantly higher proportion of Cases than Controls will be poor metabolizers on CYP450 isoenzymes (CYP2B6, CYP2D6, CYP2C19, CYP3A4/5+).
|
through study completion, approximately 2 years
|
Homozygenous for short allele of SLC6A4 will result in more side effects
Time Frame: through study completion, approximately 2 years
|
Our co-primary aim is to test the hypothesis that a statistically significantly higher proportion of Cases than Controls will be homozygenous for the short allele of SLC6A4.
|
through study completion, approximately 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: William Jangro, MD, Thomas Jefferson University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13P.25
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Lawson Health Research InstituteTerminated
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
Clinical Trials on Genocept Assay
-
Tianjin Medical University General HospitalCompletedDetection Autoantibody of Myasthenia GravisChina
-
Janssen Diagnostics, LLCTerminated
-
Janssen Diagnostics, LLCTerminated
-
Beckman Coulter, Inc.Terminated
-
Gen-Probe, IncorporatedCompletedChlamydia Trachomatis | Neisseria Gonorrhoeae InfectionUnited States
-
Oxford ImmunotecTerminated
-
Fred Hutchinson Cancer CenterFox Chase Cancer Center; City of Hope Medical Center; Stanford University; Cedars-Sinai... and other collaboratorsCompletedEpithelial Ovarian CancerUnited States
-
Abbott Diagnostics DivisionCompleted
-
Pierian BiosciencesCompletedSarcoma, Soft Tissue | Breast Neoplasms | Lung Neoplasms | Ovarian NeoplasmsUnited States
-
Huashan HospitalSuspended